Bioventus Reaches Milestone with 2 Million DUROLANE® Treatments Worldwide
22.9.2020 17:30:00 EEST | Business Wire | Press release
Bioventus, a global leader in Innovations For Active Healing, is celebrating a milestone and recognizing more than 2 million treatments worldwide with DUROLANE, its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). DUROLANE is the original single injection hyaluronic acid therapy, has helped patients in nearly 30 countries and is a trusted therapy for clinicians in the management of OA.
Proven safe and effective, DUROLANE has more clinical studies than any other US single-injection HA, and has also been proven to provide greater reduction in OA knee pain versus Synvisc-One®.1,2 It has longer lasting pain relief versus a steroid injection, is safe and repeated use of DUROLANE does not increase the incidence of adverse events.3,4
DUROLANE is available in its original 3ml syringe for treatment of large joints and in a 1ml syringe, known as DUROLANE SJ, to enable treatment of small joints.* Both are produced using a natural, safe and proven technology called NASHA ® . This process yields a high molecular weight stabilized HA, which is a naturally occurring molecule that provides lubrication and cushioning in a normal joint.
“The US launch of DUROLANE in 2018 boosted our growth to more than 2 million treatments and we are very proud of this milestone. Still, there are many more patients to reach,” said John Nosenzo, Chief Commercial Officer, Bioventus. “In the US, more than 14 million people are afflicted with knee OA and osteoarthritis overall affects more than 240 million globally.5,6 Returning people to active lifestyles is our commitment to the market and we are pleased that DUROLANE is serving the needs of clinicians and the OA patients they treat.”
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the company on LinkedIn and Twitter.
Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
*DUROLANE SJ is not available in the US.
Summary of Indication for Use: DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen. Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Full prescribing information can be found in product labeling, at www.DUROLANE.com , or by contacting Bioventus Customer Service at 1-800-836-4080.
NOTE: The above indications presented are for the US market; indications may vary by country. Contact your local Bioventus representative or visit www.durolane.com/uk/selection for prescribing information specific to your market.
1. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 2. DOF RPT-001111 3. Leighton R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2017. 5. Arthritis Foundation. What is osteoarthritis? Accessed February 9, 2019. www.arthritis.org/about-arthritis/types/osteoarthritis/what-is-osteoarthritis.php 6. Hawker GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol. 2019;37 Suppl 120(5):3-6.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005067/en/
Contact information
Thomas Hill
919-474-6715
thomas.hill@bioventusglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
In Line With the LEAP | 28 Portfolio Rotation Strategy, Bureau Veritas Signs an Agreement to Sell Its Oil & Petrochemicals and Coal Testing and Inspection Business30.6.2026 08:30:00 EEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces that it has entered exclusive negotiations with Triton Partners regarding the sale of its Oil & Petrochemicals and Coal testing and inspection business. This strategic divestment is in full alignment with the Group’s LEAP | 28 strategy. The proposed transaction would include the Oil & Petrochemicals and Coal testing and inspection activities. In 2025, this business generated approximately EUR 450 million in revenue operating a global network across multiple countries, with a significant footprint of operational sites and employees. This business grew at a lower rate than the Group and is margin dilutive. It is included within Bureau Veritas’ “Optimize value and impact” portfolio and reported under the Agri-Food & Commodities division. The transaction supports the strategic objective to increase exposure to higher growth and margin businesses. A key milestone in LEAP | 28 portfolio rotati
Corient Accelerates European Growth With the Addition of Letus Private Office30.6.2026 08:15:00 EEST | Press release
Corient today announced an agreement to acquire Letus Private Office (“Letus”), an independent multi-family office and wealth advisory firm serving entrepreneurs, founders and other ultra-high-net-worth individuals and families across France and Europe. The acquisition, subject to closing, builds on recent transactions that have made Corient the world’s largest multi-family office and non-bank wealth manager focused on ultra-high-net worth and high-net-worth clients. Paris-based Letus was founded in 2016 and is led by Managing Partners Anice Chlagou, Stephen Lasry and Alexandre Tsouli, and Partner Sacha Levy. It manages and administers approximately €4.1 billion (about US$5 billion). Letus serves ultra-high-net worth clients, primarily entrepreneurs and their families, providing comprehensive, bespoke services that integrate all aspects of wealth management and family office functions, including investment management, wealth and estate planning, financing, legal and tax support, and ph
Hengrui’s Heng Yi ® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease30.6.2026 08:00:00 EEST | Press release
Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free platform technology, announce today that on June 23, 2026, the China National Medical Products Administration (NMPA) has approved Heng Yi® (0.1% cyclosporine ophthalmic solution) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and improve the sign of the disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629052295/en/ Heng Yi Heng Yi® is the first and only water-free 0.1% cyclosporine ophthalmic solution and the second dry eye disease drug product approved in China based on the EyeSol® platform technology, following the approval of Heng Qin® (perfluorohexyloctane ophthalmic solution) in 202
“BOCCHI THE ROCK!” SeisyunComplex Premiered on June 20!30.6.2026 08:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625185578/en/ We are pleased to announce that the first screening of “BOCCHI THE ROCK!” SeisyunComplex, a new projection mapping work inspired by the highly popular anime “BOCCHI THE ROCK!”, was held on Saturday, June 20. Following its premiere, the work will be screened throughout the year as part of the weekday and weekend lineup of “TOKYO Night & Light”. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.4 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivat
Nebex Raises $30M Seed Round Led by GV to Build Market Infrastructure for the Global Space Economy29.6.2026 18:38:00 EEST | Press release
Nebex, the market infrastructure platform for the global space economy, announced a $30M seed investment led by GV (Google Ventures), with participation from other top-tier venture funds. The company also announced a banking relationship with J.P. Morgan. The capital raise and new banking relationship will help Nebex scale its platform and connect sovereign space programs with the founders and companies building new technologies to serve the space industry. "We built Nebex because we've seen firsthand that ambitious space founders struggle to deliver complex sovereign programs due to the lack of capital markets infrastructure that supports revenue and cashflow. This is something that exists in nearly every other industry," said Tejpaul Bhatia, CEO of Nebex. "Support from these organizations gives Nebex the additional leverage and financial infrastructure to build the global space economy at the scale it demands.” Since its inception, the space industry has run on a closed loop with a h
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom